Crime & Law · India

USFDA issues warning letter to Dabur over manufacturing lapses

The U.S. Food and Drug Administration (USFDA) has issued a warning letter to Dabur India Limited concerning Current Good Manufacturing Practice (CGMP) lapses at its Silvassa plant. The letter cites issues related to data integrity and manufacturing processes. The specific details of the lapses were not further elaborated in the provided coverage.

How outlets across the spectrum covered it

Left 0 · Centre 3 · Right 0   n = 3

More balanced coverage on Paksh →